I’m a layman science guy, but not surprised IL-6
I’m a layman science guy, but not surprised IL-6 inhibitors aren’t doing much.
If my memory serves, IL-6 and IL-4 work in a balance. The ratio between them is important.
Rantes attracts too many of IL-6 inflammatory cytokine to infection location.
Stop Rantes from attracting IL-6 with a CCR5 inhibitor (Leronlimab) and IL-6 and 4 rebalance.
IL-6 inhibitors, even if they work, just treat a symptom, not the underlying (upstream) issue.
This is more of a lay-question for discussion, than a statement of fact.
Thanks,
Chazzle
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
AI's New Role in Wealth Management Just when you think you've seen it all, along comes a partnership that shakes things up. Beemo Automation is teaming up with Choreo, a heavyweight in the tax-focused registered investment adviser world, to infuse some AI prowess where it matters. Choreographing their moves, they're looking to build something that's not just functional...
Continue Reading
When it comes to honoring legacy and future within the Black beauty industry, the 2026 Beauty Icon Awards seem ready to steal the spotlight. Set to take place on October 10th at Atlanta's Riverside EpiCenter, this gathering is more than just a fancy shindig – it's a tribute to Black beauty's massive influence on culture and commerce. Celebrating Pioneers and Innovators...
Continue Reading
Unifying Molecular Diagnostics for Better Cancer Care In the chaos of today’s healthcare, Aranscia is aiming to rewrite the book on how we handle cancer diagnostics by teaming up with Northside Hospital Cancer Institute. Now, instead of fumbling through disconnected systems, they plan to glue the pieces together with a blend of their own and borrowed tech. This...
Continue Reading
Shaking Up the Job Market with AI Skills What's shaking things up this time around? Handshake's dramatic unveiling of its AI Skills Studio, that's what. While the world spins on its financial axis, Handshake's showing up with a toolkit that's not just geeky gobbledygook. They're dead set on prepping job seekers with the nitty-gritty of AI know-how hosted in a rather...
Continue Reading
A Fresh Start for Young Careers with CareerPath You remember the time in life when we thought just having a degree meant something? Well, the game’s changed, and now it’s a twisted jungle where young folks struggle to find their footing. Partners International, a name I’m no stranger to—known for their human capital wizardry—seems to have noticed this chaotic...
Continue Reading
Reimagining Streaming: GRAI Buys Hangout FM The music streaming game has just been dealt a fresh hand. GRAI, an AI-driven music company, has snatched up Hangout FM, looking to ignite a social revolution in how we experience music. Sitting here, I'm thinking about all those playlists we've built but never truly shared. This acquisition might just change that by combining...
Continue Reading
iFranchise's Unyielding Dominance in Franchise Consulting Five seconds in the franchise game, and you'd know that staying on top is a grind. But when you're iFranchise Group, it seems like the eighth time is the charm—if there ever was a need for luck. These folks have secured the number one spot in Entrepreneur magazine's Top Franchise Suppliers ranking yet again....
Continue Reading
CEER's Ambitious Leap in Automotive Innovation There's a new kid on the automotive block, and it's making some serious noise. Straight out of Jeddah, CEER has just taken the wraps off their flagship electric sedan and SUV, dubbed the EXOBOT. No small beans here—this is a full-throttle, Saudi-driven pitch into the global automotive circus. And why not? There's oil in...
Continue Reading
Pharmacy Certification Made Easy When ScriptSafe rolled out its certification service for pharmacies, it felt like the industry's straitjacket was finally coming off. We’re talking about a process that traditionally took months, cost a small fortune, and made pharmacies fill out forms like they were honing a doctoral thesis. But now, you've got ScriptSafe offering a...
Continue Reading
Bringing New Leadership to Charter Next Generation It's an intriguing time to be watching Charter Next Generation (CNG) as they just added a heavyweight to their executive team. Todd Herndon, a veteran with more than three decades of financial savvy, steps in as their new Chief Financial Officer. This is like a football team drafting a star quarterback right before the...
Continue Reading
Top 5 Most Recently Viewed Articles
Boeing Co. Faces Challenges Yet Holds Promise Boeing Co. (NYSE: BA) recently saw its shares decline after announcing another quarter impacted by both successes in the commercial sector and ongoing issues with its 777X program. Despite the current difficulties, there are indications that the airline manufacturing giant is slowly recovering from a rough patch. The Analyst...
Continue Reading
Microbot Medical Finalizes $13 Million Direct Offering Microbot Medical Inc. (NASDAQ: MBOT), a pioneering company in the medical technology sector, has successfully concluded its registered direct offering. This strategic move reflects the company’s commitment to advancing its innovative technologies designed to enhance patient care across the globe. Details of the...
Continue Reading
CND Life Sciences’ Innovative Biomarker Services in Clinical Trials In the field of medical technology, CND Life Sciences, Inc. has emerged as a pioneering force with its Syn-One Biomarker Services. These services have recently been applied in an exploratory context within a Phase 2 clinical trial conducted by ABLi Therapeutics. The study aimed to investigate...
Continue Reading
Oppenheimer Expands Emerging Markets Desk with New Leadership Oppenheimer & Co. Inc. is making significant strides in expanding its service capabilities in emerging markets. This move comes as part of their strategy to deepen relationships and enhance their offerings within the fixed income domain. Strategic Additions to the Team The investment bank recently announced the...
Continue Reading
Avenue Therapeutics Stock Hits 52-Week Low In a challenging year for Avenue Therapeutics (NASDAQ: ATXI), the pharmaceutical company's stock has reached a 52-week low, trading at $2.17. This price point signifies a significant downturn for the company, which has seen its stock value plummet by an alarming 95.35% over the past year. Investors have been wary as Avenue...
Continue Reading